Kymera Therapeutics
- Market cap
- 9.01B
- P/E (TTM)i
- -33.34
- P/Bi
- 5.97
- EPSi
- -3.69
- Div yieldi
- 0.00%
- 52W posi
- 71%
Anonymous reader poll. Unscientific, not investment advice.
About Kymera Therapeutics
Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of human diseases through the development of innovative, highly differentiated medicines. It focuses on discovering and developing novel small-molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s natural protein degradation system. The company leverages targeted protein degradation (TPD) to develop medicines that address critical health challenges and have the potential to significantly improve patients lives. Its pipeline emphasizes oral small-molecule degraders, offering a new generation of convenient and highly effective therapies. The company was founded by Bruce Lee Booth and Nello Mainolfi on September 29, 2015 and is headquartered in Watertown, MA.
- Founded
- 2015
- CEO
- Dr. Nello Mainolfi, PhD
- Employees
- 238
- Headquarters
- Watertown, Massachusetts, United States of America
- Fiscal year end
- 12-31
- Website
- kymeratx.com
Company profile
- Exchange
- US
- Symbol
- KYMR
- Market-cap rank
- #1580
- Listing date
- 2020-08-21
- Market cap
- 9.01B
- Float cap
- 7.16B
- Shares out
- 83.15M
- Float shares
- 66.04M
Sectors & themes
Quote time 2026-10-08 04:01:21 · For reference only, not investment advice and not tailored to your situation.